Use of selective serotonin reuptake inhibitors and risk of myeloid malignancy: A nationwide Danish case-control study.
Long-term Danish health records show no clear link between common antidepressants and blood cancer risk despite earlier laboratory concerns.
This large population-based Danish registry study examined whether selective serotonin reuptake inhibitor (SSRI) use influences myeloid malignancy risk across 22 years of follow-up. The scale and registry-linkage design provide high-quality pharmacoepidemiological evidence addressing preclinical signals that SSRIs may affect hematopoietic stem cell proliferation.
What the study was
- Study design
- Nationwide case-control study (Danish registry)
- Population
- 22,293 myeloid malignancy cases + 445,860 controls, Denmark
- Sample size
- 468153
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- British journal of haematology
Why it surfaced
Large nationwide pharmacoepidemiological study (n>468K) addressing SSRI-myeloid malignancy risk; robust design with national registry data spanning 21 years.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.